Affinity Asset Advisors, LLC Travere Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$7.18 - $9.82 $897,500 - $1.23 Million	125,000 New	125,000 $963,000
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $764,000 - $1.73 Million	100,000 New	100,000 $894,000
Q2 2022 Aug 12, 2022	SELL	$20.94 - $30.01 $2.09 Million - $3 Million	-100,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $1.18 Million - $1.53 Million	50,000 Added 100.0%	100,000 $2.58 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $3.65 Million - $4.68 Million	-150,000 Reduced 75.0%	50,000 $1.55 Million
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $2.6 Million - $5.01 Million	200,000 New	200,000 $4.85 Million
Q2 2021 Aug 13, 2021	SELL	$14.11 - $26.4 $3.1 Million - $5.81 Million	-220,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$23.37 - $31.77 $5.14 Million - $6.99 Million	220,000 New	220,000 $5.49 Million

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.